Elanco Animal Health Incorporated (NYSE:ELAN) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Elanco Animal Health Incorporated (NYSE:ELAN) has been given a consensus recommendation of “Moderate Buy” by the seven research firms that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $18.00.

Several equities analysts recently commented on the company. Piper Sandler reissued a “neutral” rating and issued a $19.00 target price (up previously from $18.00) on shares of Elanco Animal Health in a report on Monday, May 13th. Barclays dropped their price objective on Elanco Animal Health from $23.00 to $21.00 and set an “overweight” rating on the stock in a report on Friday.

Insider Buying and Selling at Elanco Animal Health

In other Elanco Animal Health news, Director William F. Doyle bought 15,000 shares of the business’s stock in a transaction dated Tuesday, May 21st. The shares were acquired at an average cost of $16.98 per share, with a total value of $254,700.00. Following the acquisition, the director now directly owns 76,330 shares of the company’s stock, valued at approximately $1,296,083.40. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. 0.57% of the stock is owned by company insiders.

Hedge Funds Weigh In On Elanco Animal Health

Institutional investors have recently added to or reduced their stakes in the stock. UBS Group AG increased its holdings in shares of Elanco Animal Health by 78.2% in the third quarter. UBS Group AG now owns 681,905 shares of the company’s stock valued at $7,665,000 after purchasing an additional 299,166 shares during the period. Acadian Asset Management LLC acquired a new position in Elanco Animal Health in the 3rd quarter valued at $95,000. Dark Forest Capital Management LP raised its position in Elanco Animal Health by 80.3% during the 3rd quarter. Dark Forest Capital Management LP now owns 35,779 shares of the company’s stock worth $402,000 after buying an additional 15,930 shares during the last quarter. Stifel Financial Corp lifted its stake in shares of Elanco Animal Health by 64.6% in the 3rd quarter. Stifel Financial Corp now owns 185,453 shares of the company’s stock worth $2,084,000 after acquiring an additional 72,814 shares during the period. Finally, Federated Hermes Inc. boosted its holdings in shares of Elanco Animal Health by 0.6% in the third quarter. Federated Hermes Inc. now owns 2,051,833 shares of the company’s stock valued at $23,063,000 after acquiring an additional 11,846 shares in the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.

Elanco Animal Health Stock Up 1.1 %

Shares of NYSE ELAN opened at $14.43 on Monday. Elanco Animal Health has a 12-month low of $8.52 and a 12-month high of $18.80. The stock has a market cap of $7.13 billion, a P/E ratio of -5.45, a PEG ratio of 1.40 and a beta of 1.45. The company has a current ratio of 3.29, a quick ratio of 1.96 and a debt-to-equity ratio of 0.95. The business’s fifty day simple moving average is $16.43 and its 200-day simple moving average is $15.71.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Wednesday, May 8th. The company reported $0.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.26 by $0.08. Elanco Animal Health had a positive return on equity of 5.98% and a negative net margin of 29.83%. The business had revenue of $1.21 billion during the quarter, compared to analysts’ expectations of $1.18 billion. During the same quarter last year, the business posted $0.45 EPS. The business’s quarterly revenue was down 4.1% compared to the same quarter last year. As a group, equities analysts predict that Elanco Animal Health will post 0.93 EPS for the current fiscal year.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.